Treating Non-Small Cell Lung Cancer: Evolution from Chemotherapy to Targeted Therapies

 

About the episode

The treatment landscape for lung cancer has changed dramatically in the last decade and physicians are now faced with many treatment options. 
Drs. George Simon and Matt Rioth talk about how gaining access to molecular information transformed the practice of medicine, effectively navigating the complexities of clinical trials, and using real-world data to guide treatment decision-making.  
Relevant Research
Biomarker testing rates among patients with advanced non-squamous non-small cell lung cancer treated within large community health systems in the US

Skip ahead

[8:15] How gaining access to molecular information transformed the practice medicine 
[10:30] Choosing the initial line of therapy for patients who fall outside of what has been studied in clinical trials
[17:04] Gaining patient’s consent to capture real-world data to help inform care of other patients 
[18:19] Clinical trials as an integral part of cancer care
[23:27] Reducing the inefficiencies in clinical trials from an administrative and operational standpoint
[28:37] Taking action to advance biomarker precision medicine when FDA approval or expansion occurs 
[33:36] Looking to the future of cancer care